down arrow

The Chemours Co.

  • Market Cap: Small Cap
  • Industry: Specialty Chemicals
  • ISIN: US1638511089
USD
12.54
-0.42 (-3.24%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

12.4613.06

52 Week

9.1322.27
Valuation
Technical
Day's Volume

CASH

2.21 M

Shareholding (Mar 2025)

FII

16.17%

Held by 159 FIIs

DII

23.25%

Held by 77 DIIs

Promoter

0.00%

How big is The Chemours Co.?

22-Jun-2025

As of Jun 18, The Chemours Co. has a market capitalization of $1.91 billion, with net sales of $5.80 billion and a net profit of $31 million for the latest four quarters. The balance sheet shows shareholder's funds of $604 million and total assets of $7.52 billion.

As of Jun 18, The Chemours Co. has a market capitalization of 1,905.97 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 5,801.00 million and a net profit of 31.00 million for the latest four quarters ending in Mar'25, Dec'24, Sep'24, and Jun'24.<BR><BR>As of Dec'24, the balance sheet shows shareholder's funds of 604.00 million and total assets amounting to 7,515.00 million.

Read More

What does The Chemours Co. do?

22-Jun-2025

The Chemours Co. is a small-cap provider of performance chemicals in the specialty chemicals industry, with recent net sales of $1.368 billion and a market cap of approximately $1.906 billion. Key metrics include a P/E ratio of 12.00 and a dividend yield of 391.10%.

Overview: <BR>The Chemours Co. is a provider of performance chemicals in the specialty chemicals industry, operating within the small-cap market.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1,368 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,905.97 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 12.00 <BR>Dividend Yield: 391.10% <BR>Debt Equity: 6.35 <BR>Return on Equity: 28.67% <BR>Price to Book: 3.29<BR><BR>Contact Details: <BR>Address: 1007 Market St, WILMINGTON DE: 19898-1100 <BR>Tel: 1 302 7731000 <BR>Fax: 1 302 6555049 <BR>Website: https://www.chemours.com/

Read More

Who are in the management team of The Chemours Co.?

22-Jun-2025

As of March 2022, The Chemours Co. management team includes Independent Chairman Richard Brown, CEO Mark Vergnano, and Independent Directors Curtis Anastasio, Bradley Bell, Mary Cranston, Curtis Crawford, and Dawn Farrell, who oversee the company's strategic direction and governance.

As of March 2022, the management team of The Chemours Co. includes the following individuals:<BR><BR>- Mr. Richard Brown, who serves as the Independent Chairman of the Board.<BR>- Mr. Mark Vergnano, who is the President, Chief Executive Officer, and Director.<BR>- Mr. Curtis Anastasio, serving as an Independent Director.<BR>- Mr. Bradley Bell, also an Independent Director.<BR>- Ms. Mary Cranston, who is an Independent Director.<BR>- Dr. Curtis Crawford, serving as an Independent Director.<BR>- Ms. Dawn Farrell, who is an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and governance.

Read More

Is The Chemours Co. overvalued or undervalued?

20-Sep-2025

As of August 5, 2025, The Chemours Co. is considered overvalued with a P/E ratio of 12 and a decline of 5.14% in stock performance over the past year, contrasting with the S&P 500's 17.14% gain, indicating a shift from a very attractive to a risky valuation grade.

As of 5 August 2025, The Chemours Co. has moved from a very attractive to a risky valuation grade. The company appears to be overvalued given its current metrics. The P/E ratio stands at 12, while the EV to EBITDA ratio is 7.55, and the PEG ratio is exceptionally low at 0.06, indicating potential overvaluation relative to growth expectations.<BR><BR>In comparison to its peers, The Chemours Co. has a P/E ratio that is significantly lower than Westlake Corp. at 82.20 and Albemarle Corp. which has a negative P/E ratio. This suggests that while Chemours may be facing challenges, its valuation metrics are not as favorable as some competitors. Additionally, the company's recent stock performance shows a decline of 5.14% over the past year, contrasting sharply with the S&P 500's gain of 17.14%, further reinforcing the notion of overvaluation.

Read More

Is The Chemours Co. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Chemours shows a mildly bullish trend with mixed indicators, underperforming the S&P 500 significantly year-to-date and over the past year.

As of 3 October 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish moving average on the daily timeframe. However, the monthly MACD is only mildly bullish, and the Bollinger Bands indicate a mildly bearish outlook for the monthly period. The KST shows a bullish signal weekly but bearish monthly, while the OBV is mildly bullish monthly. <BR><BR>In terms of performance, Chemours has underperformed the S&P 500 significantly over longer periods, with a year-to-date return of -6.51% compared to the S&P's 14.18%, and a 1-year return of -17.84% versus the S&P's 17.82%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Debt company with Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of 2.72% and Operating profit at 2.17% over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
2

Negative results in Jun 25

3

Risky -

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Specialty Chemicals

stock-summary
Market cap

USD 2,884 Million (Small Cap)

stock-summary
P/E

12.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

130.55%

stock-summary
Debt Equity

15.48

stock-summary
Return on Equity

13.50%

stock-summary
Price to Book

12.17

Revenue and Profits:
Net Sales:
1,615 Million
(Quarterly Results - Jun 2025)
Net Profit:
-380 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.9%
0%
-16.9%
6 Months
24.53%
0%
24.53%
1 Year
-41.07%
0%
-41.07%
2 Years
-57.61%
0%
-57.61%
3 Years
-60.03%
0%
-60.03%
4 Years
-57.13%
0%
-57.13%
5 Years
-51.82%
0%
-51.82%

The Chemours Co. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Chemours Co. Hits Day High with 7.09% Surge Amid Market Decline

Chemours Co. Hits Day High with 7.09% Surge Amid Market Decline

The Chemours Co. experienced a notable stock price increase on October 13, 2025, reaching an intraday high. However, the company has struggled over the past year, with a significant decline in stock value and net profit, alongside a high debt-to-equity ratio and an attractive dividend yield.

Read More
Chemours Co. Experiences Revision in Stock Evaluation Amid Mixed Market Signals

Chemours Co. Experiences Revision in Stock Evaluation Amid Mixed Market Signals

Chemours Co., a specialty chemicals company, has seen its stock price decline recently, trading at $15.80. The stock's performance has varied against the S&P 500, with mixed returns over different time frames. Technical indicators present a complex outlook, reflecting both bullish and bearish trends.

Read More

Is The Chemours Co. technically bullish or bearish?

As of 3 October 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish moving average on the daily timeframe. However, the monthly MACD is only mildly bullish, and the Bollinger Bands indicate a mildly bearish outlook for the monthly period. The KST shows a bullish signal weekly but bearish monthly, while the OBV is mildly bullish monthly. In terms of performance, Chemours has underperformed the S&P 500 significantly over longer periods, with a year-to-date return of -6.51% compared to the S&P's 14.18%, and a 1-year return of -17.84% versus the S&P's 17.82%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
2.72%
EBIT Growth (5y)
2.17%
EBIT to Interest (avg)
2.41
Debt to EBITDA (avg)
8.11
Net Debt to Equity (avg)
6.35
Sales to Capital Employed (avg)
1.27
Tax Ratio
49.18%
Dividend Payout Ratio
174.61%
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
12.26%
ROE (avg)
33.84%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
3.41
EV to EBIT
13.13
EV to EBITDA
7.55
EV to Capital Employed
1.33
EV to Sales
0.97
PEG Ratio
0.06
Dividend Yield
377.74%
ROCE (Latest)
10.11%
ROE (Latest)
28.67%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 84 Schemes (60.53%)

Foreign Institutions

Held by 159 Foreign Institutions (16.17%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 18.06% vs -1.87% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -9,400.00% vs 50.00% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,615.00",
          "val2": "1,368.00",
          "chgp": "18.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "205.00",
          "val2": "176.00",
          "chgp": "16.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "66.00",
          "val2": "65.00",
          "chgp": "1.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-316.00",
          "val2": "-35.00",
          "chgp": "-802.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-380.00",
          "val2": "-4.00",
          "chgp": "-9,400.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "70.60%",
          "val2": "64.30%",
          "chgp": "0.63%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -4.07% vs -11.29% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 136.29% vs -141.00% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,782.00",
          "val2": "6,027.00",
          "chgp": "-4.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "759.00",
          "val2": "984.00",
          "chgp": "-22.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "264.00",
          "val2": "208.00",
          "chgp": "26.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-112.00",
          "val2": "-925.00",
          "chgp": "87.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "86.00",
          "val2": "-237.00",
          "chgp": "136.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "79.20%",
          "val2": "112.30%",
          "chgp": "-3.31%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
1,615.00
1,368.00
18.06%
Operating Profit (PBDIT) excl Other Income
205.00
176.00
16.48%
Interest
66.00
65.00
1.54%
Exceptional Items
-316.00
-35.00
-802.86%
Consolidate Net Profit
-380.00
-4.00
-9,400.00%
Operating Profit Margin (Excl OI)
70.60%
64.30%
0.63%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 18.06% vs -1.87% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -9,400.00% vs 50.00% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
5,782.00
6,027.00
-4.07%
Operating Profit (PBDIT) excl Other Income
759.00
984.00
-22.87%
Interest
264.00
208.00
26.92%
Exceptional Items
-112.00
-925.00
87.89%
Consolidate Net Profit
86.00
-237.00
136.29%
Operating Profit Margin (Excl OI)
79.20%
112.30%
-3.31%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -4.07% vs -11.29% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 136.29% vs -141.00% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About The Chemours Co. stock-summary
stock-summary
The Chemours Co.
Specialty Chemicals
The Chemours Co is a provider of performance chemicals. The Company provides a range of industrial and specialty chemicals products for markets, including plastics and coatings, refrigeration and air conditioning, general industrial, electronics, mining, and oil refining. Its segments include Fluoroproducts segment, Chemical Solutions segment and Titanium Technologies segment. Fluoroproducts segment is a provider of fluorine-based, advanced materials solutions, such as refrigerants and industrial resins and derivatives. Chemical Solutions segment is comprised of a portfolio of industrial chemical businesses, primarily operating in the Americas. Titanium Technologies segment is a manufacturer of TiO2 pigment. The Company serves various industries, such as electronics, communications, automotive, wire and cable, energy, oil and gas, and aerospace.
Company Coordinates stock-summary
Company Details
1007 Market St , WILMINGTON DE : 19898-1100
stock-summary
Tel: 1 302 7731000
stock-summary
https://www.chemours.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."